↓ Skip to main content

Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE trial): study protocol of a multicenter randomized controlled trial

Overview of attention for article published in BMC Cancer, September 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
121 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE trial): study protocol of a multicenter randomized controlled trial
Published in
BMC Cancer, September 2018
DOI 10.1186/s12885-018-4746-2
Pubmed ID
Authors

Daniëlle E. J. Starreveld, Laurien A. Daniels, Heiddis B. Valdimarsdottir, William H. Redd, Jessie L. de Geus, Sonia Ancoli-Israel, Susan Lutgendorf, Catharina M. Korse, Jacobien M. Kieffer, Flora E. van Leeuwen, Eveline M. A. Bleiker

Abstract

Cancer related fatigue (CRF) is one of the most prevalent and distressing long-term complaints reported by (non-) Hodgkin survivors. To date there has been no standard treatment for CRF in this population. A novel and promising approach to treat CRF is exposure to bright white light therapy. Yet, large scale randomized controlled trials testing its efficacy in these patients and research on potential mechanisms is lacking. The objective of the current study is to investigate the efficacy of light therapy as a treatment for CRF and to explore potential mechanisms. In a multicenter, randomized controlled trial we are evaluating the efficacy of two intensities of light therapy in reducing CRF complaints and restrictions caused by CRF in survivors of Hodgkin lymphoma or diffuse large B-cell lymphoma. Secondary outcomes include sleep quality, depression, anxiety, quality of life, cognitive complaints, cancer worries, fatigue catastrophizing, self-efficacy to handle fatigue, biological circadian rhythms of melatonin, cortisol and activity, and biomarkers of inflammation. We will recruit 128 survivors, with fatigue complaints, from academic and general hospitals. Survivors are randomized to either an intervention (exposure to bright white light) or a comparison group (exposure to dim white light). The longitudinal design includes four measurement points at baseline (T0), post-intervention at 3.5 weeks (T1), 3 months post-intervention (T2) and 9 months post-intervention (T3). Each measurement point includes self-reported questionnaires and actigraphy (10 days). T0 and T1 measurements also include collection of blood and saliva samples. Light therapy has the potential to be an effective treatment for CRF in cancer survivors. This study will provide insights on its efficacy and potential mechanisms. If proven to be effective, light therapy will provide an easy to deliver, low-cost and low-burden intervention, introducing a new era in the treatment of CRF. The study is registered at ClinicalTrials.gov on August 8th 2017( NCT03242902 ).

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 121 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 18 15%
Researcher 12 10%
Student > Ph. D. Student 9 7%
Student > Master 9 7%
Student > Postgraduate 7 6%
Other 22 18%
Unknown 44 36%
Readers by discipline Count As %
Medicine and Dentistry 17 14%
Psychology 16 13%
Nursing and Health Professions 13 11%
Biochemistry, Genetics and Molecular Biology 5 4%
Neuroscience 4 3%
Other 16 13%
Unknown 50 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2024.
All research outputs
#7,017,847
of 25,349,035 outputs
Outputs from BMC Cancer
#1,782
of 8,935 outputs
Outputs of similar age
#113,567
of 344,009 outputs
Outputs of similar age from BMC Cancer
#31
of 159 outputs
Altmetric has tracked 25,349,035 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 8,935 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,009 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 159 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.